Achromatopsia: Understanding Complete Color Blindness
Understanding Achromatopsia
Achromatopsia is a condition present from birth that affects the cone photoreceptors in the retina. Cones are the specialized cells responsible for color vision and sharp central vision in bright light. When cones do not work properly, the brain cannot process color information or form clear images in daylight.
The retina also contains rod photoreceptors, which handle vision in dim light. In achromatopsia, rods function normally. This is why people with the condition often see better in low light than in bright environments.
Most people with achromatopsia have the complete form. In complete achromatopsia, none of the three types of cone cells function. Visual acuity is typically 20/200 or worse, and there is a total loss of color discrimination. The world appears in shades of gray.
A smaller number of people have incomplete achromatopsia. In this form, one or more cone types may retain some function. Visual acuity may be as high as 20/80, and some limited color perception may be present. The severity varies from person to person.
Achromatopsia affects approximately 1 in 30,000 people worldwide (MedlinePlus Genetics). It occurs in all racial and ethnic groups. However, the prevalence is much higher in certain isolated populations. On the island of Pingelap in Micronesia, between 4% and 10% of the population has achromatopsia due to a founder mutation in the CNGB3 gene (GeneReviews, NIH). Higher rates have also been documented in certain communities where marriages between close relatives are more common (GeneReviews, NIH).
Genetics and Causes
Achromatopsia follows an autosomal recessive inheritance pattern. A child must inherit two copies of a faulty gene, one from each parent, to develop the condition. Parents who each carry one copy of the gene variant typically have normal vision and are called carriers. When both parents are carriers, each pregnancy carries a a substantial proportion chance of producing a child with achromatopsia (GeneReviews, NIH).
Because the condition requires two copies of the variant gene, it is more common in populations where marriages between relatives occur more frequently. This increases the chance that both parents carry the same gene variant.
Six genes have been identified as causes of achromatopsia: CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6. All of these genes play important roles in cone photoreceptor function. Up to the vast majority of people with achromatopsia carry mutations in either the CNGA3 or CNGB3 gene (PMC, NIH, 2024).
The CNGA3 and CNGB3 genes provide instructions for making subunits of a structure called the cyclic nucleotide-gated channel. These channels exist only in cone cells. They are essential for phototransduction, which is how the eye converts light into electrical signals the brain can understand.
When the CNGA3 or CNGB3 genes carry mutations, the cone cells either produce fewer channel subunits or produce subunits that do not work properly. The channels cannot open and close correctly. This disrupts the flow of charged particles across the cone cell membrane. The cell cannot generate the electrical signals that carry visual information to the brain. The result is cone cells that cannot respond to light.
Who Is Affected and Risk Factors
Any person can be born with achromatopsia if both parents are carriers of a variant in the same achromatopsia gene. The condition affects males and females equally. Certain populations carry a higher risk due to founder mutations. A founder mutation is a gene variant that becomes common in a small, isolated community.
The best-known example is the island of Pingelap in Micronesia. A typhoon in the 1770s reduced the population to roughly 20 survivors. One survivor carried the CNGB3 variant, and today between a small percentage and a notable percentage of the Pingelapese population has achromatopsia (GeneReviews, NIH).
Consanguinity, or marriage between blood relatives, increases the chance that both parents share the same recessive gene variant. In communities where consanguineous marriages are traditional, the rate of autosomal recessive conditions including achromatopsia tends to be higher. Genetic counseling can help families in these communities understand their risks.
A family history of achromatopsia or carrier status is the strongest individual risk factor. If one child in a family is diagnosed, genetic testing of the parents can confirm carrier status and help predict the risk for future pregnancies. Siblings of an affected child have a two-thirds chance of being carriers even if they have normal vision (GeneReviews, NIH).
Signs and Symptoms
Achromatopsia is typically first noticed when a baby is around six months of age. Parents or pediatricians may observe nystagmus (involuntary, rhythmic eye movements) within the first few weeks of life. Babies with achromatopsia often squint, close their eyes, or turn away from bright light due to severe photophobia (light sensitivity).
A distinctive finding on examination is the paradoxical pupil response. In a normal eye, the pupil constricts in bright light and dilates in dim light. In achromatopsia, the pupil may briefly constrict when the light is dimmed rather than brightened.
Visual acuity in complete achromatopsia is typically 20/200 or less. This meets the legal definition of blindness in the United States. In incomplete achromatopsia, acuity may range from 20/80 to 20/200. A small central scotoma (a blind spot in the center of the visual field) is common. Many people develop eccentric fixation, meaning they learn to look slightly off-center to see objects more clearly.
People with complete achromatopsia see the world entirely without color. Everything appears in varying shades of gray. Those with incomplete achromatopsia may perceive some colors, but color discrimination is still severely reduced. Standard color vision tests confirm complete or near-complete loss across all color axes.
Photophobia is one of the most disabling symptoms. Outdoor environments, fluorescent lighting, and bright screens can cause significant discomfort and further reduce already limited vision. Because rod cells function best in dim light, many people with achromatopsia see better indoors or on overcast days than in bright sunlight.
Diagnosis and Testing
A retina specialist or pediatric ophthalmologist may suspect achromatopsia based on nystagmus, photophobia, and poor visual acuity in an infant or young child. A thorough eye exam will assess pupil responses, visual acuity, and color vision. The paradoxical pupil response can be a helpful early clue.
The retina itself often appears structurally normal on standard examination. This can make initial diagnosis challenging. Some patients may show subtle changes in the fovea (the center of the retina) over time.
Electroretinography (ERG) measures the electrical activity of the retina in response to light. ERG is the most important clinical test for achromatopsia. In achromatopsia, cone responses are severely reduced or absent while rod responses remain normal. This pattern strongly supports the diagnosis. It also helps distinguish achromatopsia from similar conditions such as cone dystrophy or Leber congenital amaurosis.
Genetic testing confirms the diagnosis by identifying two disease-causing copies in one of the six known achromatopsia genes. Confirming the specific gene involved is important for diagnosis. It also determines whether a person may be eligible for future gene therapy clinical trials.
Optical coherence tomography (OCT) creates detailed cross-sectional pictures of the retina. In some people with achromatopsia, OCT reveals disruption or thinning of the cone photoreceptor layer in the fovea. In others, the retinal structure may appear relatively preserved. OCT findings can help monitor the condition over time and may serve as a measure in clinical trials.
Treatment Options
As of now, there is no approved treatment that restores cone function in achromatopsia. Management focuses on reducing symptoms and maximizing usable vision. Children should be monitored for refractive errors. Many people with achromatopsia have significant farsightedness (hyperopia), though nearsightedness (myopia) also occurs. Corrective glasses or contact lenses can sharpen vision to the extent possible.
Reducing light exposure is central to improving comfort and function. Options include:
- Dark-tinted glasses or sunglasses with high UV protection for outdoor use
- Special filter lenses that block specific wavelengths of light
- Red-tinted contact lenses, which can reduce glare and may improve visual acuity
- Wide-brimmed hats and visors for additional light shielding outdoors
A range of tools can help people with achromatopsia function more effectively in daily life and school. These may include:
- Handheld or electronic magnifiers for reading
- Large-print textbooks and high-contrast materials
- Screen readers and text-to-speech software
- Preferential seating away from windows or bright overhead lights
- Adjustable lighting at workstations
An evaluation by a low vision specialist can identify the best combination of aids. Occupational therapists may also help adapt workplaces and daily routines.
Gene therapy for achromatopsia is an active area of research. As of 2024, five gene therapy clinical trials have been registered, targeting either the CNGA3 or CNGB3 gene. These two genes are the focus because mutations in them account for up to 90% of cases (PMC, NIH, 2024).
In these trials, a working copy of the gene is packaged into an adeno-associated virus carrier. It is delivered to the retina through a subretinal injection performed during vitrectomy (a surgery to remove the gel inside the eye). Early results have shown an acceptable safety profile and improvements in some measures of visual function. However, these therapies remain experimental. No gene therapy for achromatopsia has received regulatory approval.
Living with Achromatopsia
Early intervention is key. Children with achromatopsia benefit from working with low vision specialists, orientation and mobility instructors, and teachers of the visually impaired. Schools can provide individualized education plans that include adjusted lighting, enlarged materials, and additional time on tests. Parents can help by creating low-glare environments at home.
Genetic counseling is recommended for families affected by achromatopsia. A genetic counselor can explain the inheritance pattern and discuss the meaning of genetic test results. They can also assess the risk for future children and connect families with clinical trial opportunities. Carrier testing is available for at-risk family members.
Because gene therapy for achromatopsia is advancing through clinical trials, staying connected with research developments is important. Genetic testing to identify the specific mutation can determine whether a person may qualify for current or future trials. Patient registries maintained by advocacy groups can help match eligible individuals with appropriate studies.
When to See a Retina Specialist
Parents who notice involuntary eye movements, severe light sensitivity, or apparent difficulty seeing in their infant should seek evaluation promptly. A pediatric ophthalmologist or retina specialist can perform the testing needed to determine whether achromatopsia or another retinal condition is present. Early diagnosis allows families to begin appropriate vision support.
People who have been diagnosed with achromatopsia should continue to see a retina specialist periodically. Regular visits allow monitoring of retinal structure with OCT and updating of prescriptions. A retina specialist can also provide guidance on emerging treatments and help determine eligibility for gene therapy clinical trials.
Questions and Answers
Yes. People with achromatopsia are not totally blind. Their rod photoreceptors function normally, so they can see shapes, movement, and contrast, especially in dim lighting. Visual acuity is significantly reduced, typically to 20/200 or less in complete achromatopsia. There is no color perception. However, most people with the condition can navigate their environment and perform many daily tasks with appropriate adaptations.
No. Common color blindness, such as red-green color deficiency, affects how a person distinguishes certain colors. It does not reduce visual acuity or cause light sensitivity. It typically involves one type of cone not working correctly. Achromatopsia involves loss of function of all three cone types. This results in a much more severe condition affecting acuity, light tolerance, and all color perception.
Gene therapy for achromatopsia is in active clinical development. As of 2024, five clinical trials at the phase I/II stage have been registered, targeting CNGA3 or CNGB3 mutations. Early results have been encouraging in terms of safety and some measures of visual improvement. However, gene therapy for achromatopsia has not yet been approved by any regulatory agency. It is not yet known when a therapy will become commercially available. Genetic testing now can help determine future eligibility.
Achromatopsia is generally a stable condition. Visual acuity, color vision, and light sensitivity remain relatively constant throughout life for most people. Some imaging studies have shown subtle structural changes in the cone layer over many years. These changes do not typically lead to noticeable additional vision loss. Rod function, which supports peripheral and low-light vision, is preserved.
If a person with achromatopsia has a partner who is not a carrier of the same gene variant, all of their children will be carriers but will have normal vision (GeneReviews, NIH). If the partner is also a carrier of the same achromatopsia gene, each child has a more than half chance of being a carrier with normal vision and a more than half chance of having achromatopsia (GeneReviews, NIH). Genetic counseling can help couples understand their specific risk based on genetic testing.